ATC | B/G | Ingredients | code | Registration Nb | Name | Dosage | Presentation | Form | Route | Agent | Laboratory | Country | Price | Pharmacist Margin | Stratum | Responsible Party Name | Responsible Party Country | Exch_date | %SUBSIDY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
L04AC05 | BioTech | Ustekinumab - 130mg | 9150/945 | 59017/1 | STELARA | 130mg | 1 | Injectable concentrate for solution | Infusion | Abela Frères S.A.L. | Cilag AG | Switzerland | 222,845,264 L.L | 2.44 | E2 | Janssen Cilag International NV | Belgium | 2/5/2024 | 0 |
ATC | B/G | Ingredients | code | Registration Nb | Name | Dosage | Presentation | Form | Route | Agent | Laboratory | Country | Price | Pharmacist Margin | Stratum | Responsible Party Name | Responsible Party Country | Exch_date | %SUBSIDY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
L04AC05 | BioTech | Ustekinumab - 130mg | 9150 | 59017/1 | STELARA | 130mg | 1 | Injectable concentrate for solution | Infusion | Abela Frères S.A.L. | Cilag AG | Switzerland | 36,370,199 L.L | 2.44 | E2 | Janssen Cilag International NV | Belgium | 2/5/2024 |